CHI, Cambridge Healthtech Institute

Conference Menu

Overview

Agenda-Day One

Agenda-Day Two

Download PDF

Register

Hotel & Travel

Press Pass

Request Brochure

Send to a Colleague

PSS Homepage

Corporate
Sponsor:

Lead
Sponsoring Publication:

Lead Web
Partner:

Sponsoring Publications:

Web Partners:

Overview

	Models to Evaluate the ROI of New Technologies
	Can Licensing Strategies Alter the High Rate of Failure for New Chemical Entities?
	Symbiosis of Large Pharma and Biotech: Getting the Interactions Right Through to Due Diligence
	Complementing Internal R&D with External Innovation
	Strategies to Protect Intellectual Property During Negotiations

Presentations from:

2004 Emerging Company Partnering Forum
November 18, 2004

3DM, Inc.
Dynogen Pharmaceuticals, Inc.
Genodive
Gloucester Pharmaceuticals, Inc. Quintessence Biosciences, Inc.
Reify Corporation
TransTech Pharma Inc

Expert Critique Panel
Gregory Bell, Ph.D., M.B.A., Vice President, Pharmaceutical Practice, Charles River Associates, Robert Gould, Vice President, Licensing & External Research, Merck Research Labs, Lisa Gray, Managing Partner, Phoenix IP Ventures (former Director at GSK Ventures)
Michael Lytton, J.D., M.Sc., General Partner, Oxford Bioscience Partners

"Pharmaceutical Strategy Series partnering and networking events are always a great opportunity to exchange ideas and meet key decision makers within the industry."
- Ron Newbold, Ph.D., Senior Director, Strategic Research Initiatives, External Scientific Affairs, Merck & Co.